The AmpliChip® CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism-Reference-Cited by-同舟云学术

The AmpliChip® CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism

Published:2012-08 Issue:8 Volume:16 Page:897-903
ISSN:1945-0265
Container-title:Genetic Testing and Molecular Biomarkers
language:en
Short-container-title:Genetic Testing and Molecular Biomarkers

Author:

Müller Daniel J.¹,Brandl Eva J.¹,Hwang Rudi¹,Tiwari Arun K.¹,Sturgess Jessica E.¹,Zai Clement C.¹,Lieberman Jeffrey A.²,Kennedy James L.¹,Richter Margaret A.¹³

Affiliation:

1. Pharmacogenetics Research Clinic, Neurogenetics Section, Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.

2. Department of Psychiatry, Columbia University, New York, New York.

3. Department of Psychiatry, Sunnybrook Health Sciences Centre, and University of Toronto, Toronto, Ontario, Canada.

Publisher

Mary Ann Liebert Inc

Subject

Genetics (clinical),General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/gtmb.2011.0327

Reference56 articles.

1. Cytochrome P4502D6 genotype does not determine response to clozapine.

2. Pharmacogenomics in schizophrenia: the quest for individualized therapy

3. Epileptiform Seizure After Sertraline Treatment in an Adolescent Experiencing Obsessive-Compulsive Disorder and Presenting a Rare Pharmacogenetic Status